Icro Meattini, MD

Icro Meattini, MD, an associate professor in the Department of Clinical and Experimental Biomedical Sciences at the University of Florence; as well as a clinical oncologist in the Radiation Oncology Unit in the Oncology Department and head of the Breast Unit and Breast Cancer Multidisciplinary Team at Florence University Hospital

Articles by Icro Meattini, MD

Dr Meattini on Adjuvant Radiotherapy vs Endocrine Therapy in Early Breast Cancer

ByIcro Meattini, MD

March 7th 2025

Icro Meattini, MD, discusses the benefits of adjuvant radiation therapy vs endocrine therapy in patients with luminal-like early breast cancer.

Icro Meattini, MD

Articles by Icro Meattini, MD

Dr Meattini on Adjuvant Radiotherapy vs Endocrine Therapy in Early Breast Cancer

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD

Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma

Icro Meattini, ​MD

Articles by Icro Meattini, ​MD

Dr Meattini on Adjuvant Radiotherapy vs Endocrine Therapy in Early Breast Cancer

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD

Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma

Icro Meattini, MD

Articles by Icro Meattini, MD